Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?

Expert review of anticancer therapy - 1 Feb 2008

Peppercorn Jeffrey, A Carey Lisa

Abstract excerpt

Evaluation of: Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient Cyp2D6 and Cyp2c19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007). Tamoxifen is one of the most commonly used treatments for breast cancer but is not effective in all patients. We review the study by Schroth and colleagues, evaluating the correlation between genotype for CYP2D6 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antineoplastic Agents, Hormonal
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Neoplasm Recurrence, Local

Share to Probability

Share to Reference Values

Share to Tamoxifen

Source

Identifiers

PMID: 18279059
DOI: 10.1586/14737140.8.2.191

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?PMID 18279059Read ↗

Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.Semantic proximity Read ↗

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Semantic proximity Read ↗

Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.Semantic proximity Read ↗

Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling AnalysisSemantic proximity Read ↗

Pharmacogenetics of endocrine therapy for breast cancer.Semantic proximity Read ↗

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapySemantic proximity Read ↗

Should CYP2D6 be genotyped when treating with tamoxifen?Semantic proximity Read ↗

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?Semantic proximity Read ↗

Genotype-guided tamoxifen therapy: time to pause for reflection?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.